A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina
Salima
S
von Kalle
Christof
C
Schmidt
Manfred
M
Le Deist
Françoise
F
Wulffraat
Nicolas
N
McIntyre
Elisabeth
E
Radford
Isabelle
I
Villeval
Jean-Luc
JL
Fraser
Christopher C
CC
Cavazzana-Calvo
Marina
M
Fischer
Alain
A
D048868:Adaptor Proteins, Signal Transducing; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D041321:Chromosomes, Human, X; D004268:DNA-Binding Proteins / Q000235:genetics*; D015870:Gene Expression; D008040:Genetic Linkage; D015316:Genetic Therapy / Q000009:adverse effects*; D006801:Humans; D060588:LIM Domain Proteins; D018655:Lymphocyte Count; D008667:Metalloproteins / Q000235:genetics*; D016254:Mutagenesis, Insertional; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000209:etiology*; D011518:Proto-Oncogene Proteins; D012190:Retroviridae; D016511:Severe Combined Immunodeficiency / Q000628:therapy*
D048868:Adaptor Proteins, Signal Transducing; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D008667:Metalloproteins; D011518:Proto-Oncogene Proteins